Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Femasys (NASDAQ:FEMY) vs. Co-Diagnostics (NASDAQ:CODX) Critical Survey | news.google.com • |
Has Co-Diagnostics (CODX) Outpaced Other Medical Stocks This Year? | news.google.com • |
CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates | news.google.com • |
Is CoDiagnostics (CODX) Outperforming Other Medical Stocks This Year? | news.google.com • |
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains? | news.google.com • |
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast | prnewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -0.21 | N/A | N/A | N/A |
2024-03-14 | 2023-12 | 0 | -0.5 | N/A | N/A |
2023-11-09 | 2023-09 | -0.29 | -0.2 | 0.09 | 31.03% |
2023-11-09 | 2023-09 | -0.29 | N/A | N/A | N/A |
2023-08-10 | 2023-06 | -0.24 | -0.31 | -0.07 | -29.17% |
2023-08-10 | 2023-06 | -0.24 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-05-14 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-03-19 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-02-22 | HC Wainwright & Co. | Upgrade | Buy | |
2022-11-13 | HC Wainwright & Co. | Upgrade | Buy | |
2022-08-14 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-05-23 | BENSON REED L | General Counsel | 3.17K | Conversion of Exercise of derivative security |
2023-11-21 | BROWN BRIAN LEE | Chief Financial Officer | 213.22K | Stock Award(Grant) |
2023-11-21 | DURENARD EUGENE A | Director | 85.00K | Stock Award(Grant) |
2023-11-21 | EGAN DWIGHT H | Chief Executive Officer | 270.88K | Stock Award(Grant) |
2023-11-21 | MURPHY TED | Director | 97.50K | Stock Award(Grant) |
2023-11-21 | NELSON JAMES B | Director | 85.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.78M | 1.98M | 5.79% |
2023-06-29 | Renaissance Technologies, LLC | 653.70K | 725.61K | 2.12% |
2023-06-29 | Blackrock Inc. | 506.51K | 562.22K | 1.65% |
2023-06-29 | Geode Capital Management, LLC | 302.16K | 335.39K | 0.98% |
2023-06-29 | Bridgeway Capital Management, Inc. | 272.90K | 302.92K | 0.89% |
2023-06-29 | Bank Of New York Mellon Corporation | 145.62K | 161.64K | 0.47% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.28M | 1.42M | 4.15% |
2023-06-29 | Vanguard Extended Market Index Fund | 444.78K | 493.70K | 1.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 272.90K | 302.92K | 0.89% |
2023-05-30 | Fidelity Extended Market Index Fund | 165.22K | 180.09K | 0.54% |
2023-08-30 | iShares Micro Cap ETF | 69.84K | 86.60K | 0.23% |
2023-05-30 | Fidelity Total Market Index Fund | 53.59K | 58.41K | 0.17% |
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
$CODX FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test https://finance.yahoo.com/news/fda-policy-change-allow-rapid-103000584
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
-
$CODX I love the random bear comments bashing the stock as it clearly rose 50% in premarket. Yes, yes... $CODX is a scam, no one wants the kits, blah blah blah - and it is not the least bit comical that you have decided to share this vital information and investment advice as our stock is on the path to doubling in less than twenty four hours.
Thanks for the unsolicited and certainly unbiased investment advice bears. Yeah, $CODX was an awful thing to buy yesterday at 8.xx$ and I gravely regret being 50% up day on day.
What a mercy it is that you are here to save my portfolio by saying up is down and black is white.
Time to cover bears. This squeeze will be fun.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
$CODX going to add on the dip after open. Picked up 2250 shares at 8.86 the other day. Every time this goes to single digits I accumulate. Every time it goes over $17 I sell. It’s nuts. Was hoping to add at $6 today and was shocked to see double digits. Will average up I guess on the morning dip / profit taking at open and then hold until above 18$ for half and hold the rest for 21$ then repeat.
Short squeeze may produce an ATH today actually. Bears got very greedy.
-
$CODX The bears are freaking out. The squeeze should bring us above $20 alone.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
Officials with a Salt Lake City-based biomedical company called Co-Diagnostics said Monday the firm had developed a test for the virus in early January and received clearance from top European regulators on its use.
But expedited approval for the test from the U.S. Food and Drug Administration is still forthcoming, said Seth Egan, the company’s international head of sales.
The small publicly traded company is capable of manufacturing 50,000 tests per day at its Utah facilities, at a cost of $10 per test, and already ships testing kits to Italy, Turkey, England and Australia, Egan said.
“We could supply all of the testing needs in Utah and greater areas around us easily,” he told a group of tech leaders in a Monday conference call about the virus. “We sit here a little amazed that we have a test that is available in European nations but we can’t sell it as a clinical diagnostic in our own home state.”
An official with Silicon Slopes, representing more than 6,000 Utah technology companies, said the group would make financial backing and support available if needed in the coming days to help secure that emergency FDA approval.
-
-
https://youtu.be/aiVqcIyMyR0 if all you want this to be big send it to the news.
-
-
Co-Diagnostics CEO Dwight Egan commented, "We are pleased to enter into these agreements with PreCheck. They are part of a strong demand we are experiencing for our Covid-19 tests. The agreements also highlight Co-Diagnostics’ commitment to supporting the global response to coronavirus. As such, we are delighted to have PreCheck as a customer, focused on distributing these products in Russia and Ecuador."
Further information is available in the Company’s regulatory filing, which can be accessed at www.sec.gov.
-
Femasys (NASDAQ:FEMY) vs. Co-Diagnostics (NASDAQ:CODX) Critical Survey
news.google.com • -
Has Co-Diagnostics (CODX) Outpaced Other Medical Stocks This Year?
news.google.com • -
CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
news.google.com • -
Is CoDiagnostics (CODX) Outperforming Other Medical Stocks This Year?
news.google.com • -
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'
investorplace.com • -
Why Co-Diagnostics Stock Slipped Today
fool.com • -
Co-Diagnostics set to expand OEM deal with Bio Molecular Systems at AACC expo
proactiveinvestors.com • -
CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests
investorplace.com • -
Why Co-Diagnostics Stock Is Rising Today
fool.com • -
Why Co-Diagnostics Is Running Higher Today
fool.com • -
Co-Diagnostics develops principal design work on monkeypox PCR test
proactiveinvestors.com • -
Why Co-Diagnostics Stock Is Trading Higher After Hours
benzinga.com • -
Co-Diagnostics adds four new experts to its Scientific Advisory Board
proactiveinvestors.com • -
Why Co-Diagnostics Is Soaring Today
fool.com • -
Why Co-Diagnostics Shares Are Trading Higher Today
benzinga.com • -
Co-Diagnostics: Swinging For The Fences
seekingalpha.com • -
4 Stocks With High Growth Potential
gurufocus.com • -
7 Stocks to Buy to Hedge Against Omicron Variant Risks
investorplace.com • -
Co-Diagnostics partners with TiiCKER to increase connection with retail investors
proactiveinvestors.com • -
Co-Diagnostics sees record 3Q revenue of $30.1M on Logix Smart coronavirus test sales
proactiveinvestors.com • -
Co-Diagnostics says its Logix Smart COVID-19 test has been approved for sale in the UK
proactiveinvestors.com • -
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform
proactiveinvestors.com • -
Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion
proactiveinvestors.com • -
Co-Diagnostics says its Logix Smart ABC Test is authorized for use in Mexico
proactiveinvestors.com • -
Why Co-Diagnostics Is A Solid Covid-19 Play
seekingalpha.com • -
Co-Diagnostics sees 2Q revenue rise by 13.8% driven by sales of the Logix Smart COVID-19 Test
proactiveinvestors.com •